Testing etavopivat in children with sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 18 years old.
- They must have a confirmed diagnosis of sickle cell disease (like HbSS or HbSβ0-thalassemia).
- Their hemoglobin level must be between 5.5 and 10.5 g/dL.
- They must have had at least 2 sickle cell pain crises in the last year, or another serious complication like hospitalization or protein in urine.
- They cannot be on regular blood transfusions or have had a blood transfusion in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
This study tests an investigational oral pill called etavopivat that may help reduce pain crises in people with sickle cell disease. You may qualify if you have frequent pain crises and are not on regular blood transfusions.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
This study tests an investigational medicine called osivelotor for people with sickle cell disease (SCD). The goal is to see if it can reduce pain crises and improve overall health. It is for adults and adolescents aged 12 and older.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.